Myelodysplastic syndromes in patients under 50 years old: A single institution experience

Massimo Breccia, Andrea Mengarelli, Marco Mancini, Francesca Biondo, Fabiana Gentilini, Roberto Latagliata, Franco Mandelli, Giuliana Alimena

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

We report on our experience relating to 62 patients with myelodysplastic syndrome (MDS) aged less than 50 years, seen at our Institution and conservatively treated from July 1983 to December 2000. Patients demographics and clinical features at diagnosis were analysed for their prognostic value on survival and on risk of transformation to acute leukaemia. The median age at diagnosis was 43 years (range 21-50). According to FAB criteria there were 30 patients with refractory anaemia (RA), 3 with refractory anaemia with ringed sideroblasts (RARS), 18 with refractory anaemia with excess of blasts (RAEB), 6 with refractory anaemia with excess of blasts in transformation (RAEB-t) and 5 with chronic myelomonocytic leukaemia (CMML). Fifty patients had evaluable cytogenetic analysis: the most frequent karyotypic change was trisomy of chromosome 8 (10%), followed by monosomy 7 (6%); partial chromosome deletions and translocations were also common abnormalities, occurring on the whole in 16% of patients. At a median follow-up of 15 months 19 patients (31%) progressed to acute myeloid leukaemia (AML). From univariate analysis we identified some features, which appeared to be predictive of outcome and risk of transformation to AML. Age above 40 years (p = 0.002) and high risk according to IPSS score (p = 0.002) were found to be predictive for a shorter survival; FAB grouping (p = 0.0001), percentage >5% of blasts in the bone marrow (p = 0.001) and high risk by IPSS score (p = 0.0003) were found to be predictive for a higher risk of transformation to AML. Presenting features in young MDS patients may identify subjects at higher risk of unfavourable outcome.

Original languageEnglish
Pages (from-to)749-754
Number of pages6
JournalLeukemia Research
Volume29
Issue number7
DOIs
Publication statusPublished - Jul 2005

Fingerprint

Myelodysplastic Syndromes
Acute Myeloid Leukemia
Refractory Anemia with Excess of Blasts
Refractory Anemia
Leukemia, Myelomonocytic, Chronic
Chromosomes, Human, Pair 10
Chromosome Deletion
Survival
Cytogenetic Analysis
Lymphocyte Activation
Leukemia
Bone Marrow
Demography

Keywords

  • IPSS
  • Myelodysplastic syndromes
  • Prognostic factors
  • Young patients

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Breccia, M., Mengarelli, A., Mancini, M., Biondo, F., Gentilini, F., Latagliata, R., ... Alimena, G. (2005). Myelodysplastic syndromes in patients under 50 years old: A single institution experience. Leukemia Research, 29(7), 749-754. https://doi.org/10.1016/j.leukres.2005.01.003

Myelodysplastic syndromes in patients under 50 years old : A single institution experience. / Breccia, Massimo; Mengarelli, Andrea; Mancini, Marco; Biondo, Francesca; Gentilini, Fabiana; Latagliata, Roberto; Mandelli, Franco; Alimena, Giuliana.

In: Leukemia Research, Vol. 29, No. 7, 07.2005, p. 749-754.

Research output: Contribution to journalArticle

Breccia, M, Mengarelli, A, Mancini, M, Biondo, F, Gentilini, F, Latagliata, R, Mandelli, F & Alimena, G 2005, 'Myelodysplastic syndromes in patients under 50 years old: A single institution experience', Leukemia Research, vol. 29, no. 7, pp. 749-754. https://doi.org/10.1016/j.leukres.2005.01.003
Breccia, Massimo ; Mengarelli, Andrea ; Mancini, Marco ; Biondo, Francesca ; Gentilini, Fabiana ; Latagliata, Roberto ; Mandelli, Franco ; Alimena, Giuliana. / Myelodysplastic syndromes in patients under 50 years old : A single institution experience. In: Leukemia Research. 2005 ; Vol. 29, No. 7. pp. 749-754.
@article{a34f95bfa55c456682536793d4353391,
title = "Myelodysplastic syndromes in patients under 50 years old: A single institution experience",
abstract = "We report on our experience relating to 62 patients with myelodysplastic syndrome (MDS) aged less than 50 years, seen at our Institution and conservatively treated from July 1983 to December 2000. Patients demographics and clinical features at diagnosis were analysed for their prognostic value on survival and on risk of transformation to acute leukaemia. The median age at diagnosis was 43 years (range 21-50). According to FAB criteria there were 30 patients with refractory anaemia (RA), 3 with refractory anaemia with ringed sideroblasts (RARS), 18 with refractory anaemia with excess of blasts (RAEB), 6 with refractory anaemia with excess of blasts in transformation (RAEB-t) and 5 with chronic myelomonocytic leukaemia (CMML). Fifty patients had evaluable cytogenetic analysis: the most frequent karyotypic change was trisomy of chromosome 8 (10{\%}), followed by monosomy 7 (6{\%}); partial chromosome deletions and translocations were also common abnormalities, occurring on the whole in 16{\%} of patients. At a median follow-up of 15 months 19 patients (31{\%}) progressed to acute myeloid leukaemia (AML). From univariate analysis we identified some features, which appeared to be predictive of outcome and risk of transformation to AML. Age above 40 years (p = 0.002) and high risk according to IPSS score (p = 0.002) were found to be predictive for a shorter survival; FAB grouping (p = 0.0001), percentage >5{\%} of blasts in the bone marrow (p = 0.001) and high risk by IPSS score (p = 0.0003) were found to be predictive for a higher risk of transformation to AML. Presenting features in young MDS patients may identify subjects at higher risk of unfavourable outcome.",
keywords = "IPSS, Myelodysplastic syndromes, Prognostic factors, Young patients",
author = "Massimo Breccia and Andrea Mengarelli and Marco Mancini and Francesca Biondo and Fabiana Gentilini and Roberto Latagliata and Franco Mandelli and Giuliana Alimena",
year = "2005",
month = "7",
doi = "10.1016/j.leukres.2005.01.003",
language = "English",
volume = "29",
pages = "749--754",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Ltd",
number = "7",

}

TY - JOUR

T1 - Myelodysplastic syndromes in patients under 50 years old

T2 - A single institution experience

AU - Breccia, Massimo

AU - Mengarelli, Andrea

AU - Mancini, Marco

AU - Biondo, Francesca

AU - Gentilini, Fabiana

AU - Latagliata, Roberto

AU - Mandelli, Franco

AU - Alimena, Giuliana

PY - 2005/7

Y1 - 2005/7

N2 - We report on our experience relating to 62 patients with myelodysplastic syndrome (MDS) aged less than 50 years, seen at our Institution and conservatively treated from July 1983 to December 2000. Patients demographics and clinical features at diagnosis were analysed for their prognostic value on survival and on risk of transformation to acute leukaemia. The median age at diagnosis was 43 years (range 21-50). According to FAB criteria there were 30 patients with refractory anaemia (RA), 3 with refractory anaemia with ringed sideroblasts (RARS), 18 with refractory anaemia with excess of blasts (RAEB), 6 with refractory anaemia with excess of blasts in transformation (RAEB-t) and 5 with chronic myelomonocytic leukaemia (CMML). Fifty patients had evaluable cytogenetic analysis: the most frequent karyotypic change was trisomy of chromosome 8 (10%), followed by monosomy 7 (6%); partial chromosome deletions and translocations were also common abnormalities, occurring on the whole in 16% of patients. At a median follow-up of 15 months 19 patients (31%) progressed to acute myeloid leukaemia (AML). From univariate analysis we identified some features, which appeared to be predictive of outcome and risk of transformation to AML. Age above 40 years (p = 0.002) and high risk according to IPSS score (p = 0.002) were found to be predictive for a shorter survival; FAB grouping (p = 0.0001), percentage >5% of blasts in the bone marrow (p = 0.001) and high risk by IPSS score (p = 0.0003) were found to be predictive for a higher risk of transformation to AML. Presenting features in young MDS patients may identify subjects at higher risk of unfavourable outcome.

AB - We report on our experience relating to 62 patients with myelodysplastic syndrome (MDS) aged less than 50 years, seen at our Institution and conservatively treated from July 1983 to December 2000. Patients demographics and clinical features at diagnosis were analysed for their prognostic value on survival and on risk of transformation to acute leukaemia. The median age at diagnosis was 43 years (range 21-50). According to FAB criteria there were 30 patients with refractory anaemia (RA), 3 with refractory anaemia with ringed sideroblasts (RARS), 18 with refractory anaemia with excess of blasts (RAEB), 6 with refractory anaemia with excess of blasts in transformation (RAEB-t) and 5 with chronic myelomonocytic leukaemia (CMML). Fifty patients had evaluable cytogenetic analysis: the most frequent karyotypic change was trisomy of chromosome 8 (10%), followed by monosomy 7 (6%); partial chromosome deletions and translocations were also common abnormalities, occurring on the whole in 16% of patients. At a median follow-up of 15 months 19 patients (31%) progressed to acute myeloid leukaemia (AML). From univariate analysis we identified some features, which appeared to be predictive of outcome and risk of transformation to AML. Age above 40 years (p = 0.002) and high risk according to IPSS score (p = 0.002) were found to be predictive for a shorter survival; FAB grouping (p = 0.0001), percentage >5% of blasts in the bone marrow (p = 0.001) and high risk by IPSS score (p = 0.0003) were found to be predictive for a higher risk of transformation to AML. Presenting features in young MDS patients may identify subjects at higher risk of unfavourable outcome.

KW - IPSS

KW - Myelodysplastic syndromes

KW - Prognostic factors

KW - Young patients

UR - http://www.scopus.com/inward/record.url?scp=20344367270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20344367270&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2005.01.003

DO - 10.1016/j.leukres.2005.01.003

M3 - Article

C2 - 15927670

AN - SCOPUS:20344367270

VL - 29

SP - 749

EP - 754

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 7

ER -